ENTERA BIO LTD.
(Registrant)
|
|||
By:
|
/s/ Spiros Jamas, Sc.D
|
||
Name: Spiros Jamas, Sc.D
|
|||
Title: Chief Executive Officer and Director
|
|||
• |
FDA Approval of EB613 IND and Completion of Enrollment in EB613 Phase 2 Clinical Trial in Israel: EB613, an orally delivered human parathyroid hormone (1-34) or PTH, drug candidate, is positioned
to be the first oral bone building (osteoanabolic) treatment for osteoporosis. In December 2020, the U.S. Food and Drug Administration, or FDA, approved Entera’s Investigational New Drug, or IND, application for the initial US EB613 study
in osteoporosis. Enrollment in the Phase 2 clinical trial in Israel was completed in November 2020 with 161 subjects. Assuming positive final results from this trial, Entera intends to meet with the FDA to discuss the design of a pivotal
Phase 3 non-inferiority trial examining the increase in spine bone mineral density of EB613 compared to the increase observed with Forteo® (SC PTH 1-34) and confirm the potential for approval under the 505 (b)(2) regulatory
pathway.
|
• |
Positive Final 3-Month Biomarker Data from Phase 2 Trial of EB613 in Osteoporosis: The Phase 2 study’s efficacy endpoints include an evaluation of biomarker data after 3- and 6-months of
treatment and bone mineral density data, or BMD, after 6 months of treatment. Interim 6-month BMD data reported in August 2020 indicate EB613 has a statistically significant positive impact on lumbar spine BMD in a dose dependent manner. In
the recently completed 3-month biomarker data analyses, subjects in the 2.5 mg dose group had a significant increase in bone formation biomarkers P1NP (primary endpoint) and Osteocalcin, from baseline compared to placebo. Patients in the
2.5 mg dose group also had a significant reduction in CTX. Reduction in CTX, a bone resorption marker, is correlated with a reduction in the break down of bone and is an important factor for a potential increase in BMD. Taken together,
these results are supportive of the osteoanabolic or bone building effects of EB613, and the potential of EB613 to produce meaningful significant increases in BMD at 6 months. Final data analyses including 6-month BMD data are expected the
second quarter of 2021.
|
• |
Publication of Positive Data from EB612 Phase 2a Clinical Trial in Hypoparathyroidism (HypoPT): Results from a Phase 2a clinical trial were recently published in The Journal of Bone and Mineral Research in an article, titled “Safety and Efficacy of Oral Human Parathyroid Hormone (1-34) in Hypoparathyroidism: An Open-Label Study.” The Phase 2a study achieved its primary and secondary
endpoints including a statistically significant decrease in supplemental calcium usage, maintenance of serum albumin-adjusted calcium and reduction of serum phosphate with the addition of EB612 to the standard of care. Entera is currently
working on optimizing the formulation of EB612 and the design of a Phase 2b clinical trial which the Company expects to initiate in 2022.
|
• |
Initiation of Oral GLP-2 Program: Leveraging its large molecule oral delivery platform, Entera initiated a new research program for an oral glucagon-like peptide-2 (GLP-2) analog. The only GLP-2
analog currently on the market is a once-daily injection for the treatment of short bowel syndrome with reported global sales of $574 million in 2019. In preclinical models, Entera’s oral GLP-2 analog has shown a comparable pharmacokinetic
profile to a subcutaneous injection. GLP-2 analogs, which improve intestinal absorption of nutrients and fluids, have the potential to emerge as a new class of drugs to treat a broad range of gastrointestinal and metabolic diseases. Entera
is currently evaluating different strategies to advance the oral GLP-2 program into clinical development.
|
• |
Pipeline and Collaboration Developments: The Company’s collaboration with Amgen reached its third year and Amgen has completed several studies of its drug using Entera’s oral delivery technology.
In addition, Entera continues to pursue new molecules, targets, and indications for preclinical development with a goal of building its pipeline and creating partnership opportunities.
|
Year Ended
|
||||||||
December 31,
|
||||||||
2020
|
2019
|
|||||||
REVENUE
|
$
|
365
|
$
|
236
|
||||
COST OF REVENUE
|
209
|
210
|
||||||
RESEARCH AND DEVELOPMENT EXPENSES, NET
|
6,398
|
7,199
|
||||||
GENERAL AND ADMINISTRATIVE EXPENSES
|
4,891
|
4,281
|
||||||
OPERATING LOSS
|
11,133
|
11,454
|
||||||
FINANCIAL (INCOME):
|
||||||||
Income from change in fair value of financial liabilities at fair value through profit or loss, net
|
(1,237
|
)
|
(743
|
)
|
||||
Other financial expenses (income), net
|
67
|
84
|
||||||
FINANCIAL (INCOME), net
|
(1,170
|
)
|
(659
|
)
|
||||
LOSS BEFORE TAXES
|
9,963
|
10,795
|
||||||
TAXES ON INCOME
|
20
|
−
|
||||||
NET COMPREHENSIVE LOSS FOR THE YEAR
|
$
|
9,983
|
$
|
10,795
|
LOSS PER ORDINARY SHARE:
|
||||||||
Basic
|
$
|
0.54
|
$
|
0.89
|
||||
Diluted
|
$
|
0.55
|
$
|
0.89
|
||||
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING:
|
||||||||
Basic
|
18,417,093
|
12,146,729
|
||||||
Diluted
|
18,563,675
|
12,146,729
|
December31,
|
December 31,
|
|||||||
2020
|
2019
|
|||||||
Cash and cash equivalents
|
$
|
8,593
|
$
|
15,185
|
||||
Accounts receivable and other current assets
|
516
|
451
|
||||||
Property and equipment, net
|
192
|
202
|
||||||
Other assets, net
|
961
|
865
|
||||||
Total assets
|
$
|
10,262
|
$
|
16,703
|
||||
Accounts payable and other current liabilities
|
$
|
1,841
|
$
|
2,148
|
||||
Warrant liabilities
|
1,432
|
2,444
|
||||||
Total current liabilities
|
3,273
|
4,592
|
||||||
Total Non-current liabilities
|
324
|
192
|
||||||
Total shareholders’ equity
|
6,665
|
11,919
|
||||||
Total liabilities and shareholders’ equity
|
$
|
10,262
|
$
|
16,703
|